Cancer genome analysis has identified recurrent missense mutations in the SPOP gene in 11~13% of primary prostate cancer (PC) [20–22] and in 6~8% of metastatic and castration-resistant PC [23]. The gene discussed is SPOP; the disease is pachyonychia congenita.